IndustryCompany release

Interpace Biosciences Q3 revenue rises 18% to $10.4M on thyroid testing growth

🇺🇸 Interpace Biosciences, Inc. (IDXG) · Tue 17 Nov 2026

The thyroid-focused diagnostics company reported adjusted EBITDA of $2.1M but a $1.5M loss from continuing operations, and said its pancreatic cancer test will not generate revenue before 2028.

Interpace Biosciences reported third-quarter 2026 results on 16 November, with revenue up 18% to $10.4M. The company attributed the growth to a 7% rise in thyroid test volume for its ThyGeNEXT and ThyraMIR v2 products.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Company's press release (SEC filing): Interpace Biosciences, Inc. ↗

Article written by VigiEye from the official source (Interpace Biosciences, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →